Navigation Links
Vaginal progesterone gel may improve infant outcomes and...
Date:10/2/2007

ogesterone gel may reduce early preterm birth among women with a short cervix.

When looking at a sample of 46 women with a short cervix of less than 2.8 cm, zero of those who were started on vaginal progesterone gel between 18-to-22 weeks of gestational age delivered prior to 32 weeks of gestation, while almost one in three women (29.6 percent; p=0.014) with a shortened cervix given a placebo delivered prior to 32 weeks of gestation, said Emily DeFranco, DO, primary author of the study and clinical fellow of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, and Center for Preterm Birth Research at Washington University School of Medicine in St. Louis. Additionally, the number of admissions and days spent in the neonatal intensive care unit, important measures of neonatal outcome, for babies whose moms were given vaginal progesterone gel were significantly lower than for those whose moms received placebo. Were excited about these promising clinical implications, especially if confirmed in a larger study.

Publishing these findings is an important step toward informing healthcare providers about the group of women who may benefit from vaginal progesterone by reducing their chances for having an early preterm birth, said study co-author John OBrien, M.D., affiliated with Central Baptist Hospital, Lexington, KY. There are currently no FDA-approved treatments available to help prevent preterm birth, so this research, combined with future studies, may lead to viable treatment options.

The published subset of data is from a randomized, double-blind, placebo-controlled study -- the largest study to date evaluating the effect of progesterone on early preterm birth in singletons. The report on these data, entitled Vaginal Progesterone Is Associated With a Decrease in Risk for Early Preterm Birth and Improved Neonatal Outcome in Women with a Short Cervix, is available at

Contact: Kathleen Cosgrove
kathleen.cosgrove@mslpr.com
617-937-2534
Columbia Laboratories, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Vaginal Birth After C-section Dangerous For Both Mother And Baby
2. PET Scanner detects more Vaginal cancer than CT scans
3. Vaginal Vaccine may prevent periodic infections
4. A new approach to vaginal hysterectomy
5. Dermaseptins: Potent vaginal contraceptives
6. Vaginal atrophy drug Ospemifene found effective in breast cancer Prevention
7. US surge in vaginal reconstruction
8. Increased Risk Of HIV Transmission Following Vaginal Washing
9. Risk Of AIDS Rises With Vaginal Washes
10. Vaginal massage during pregnancy avoids Episiotomy procedure
11. Vaginal Gel That Protects Against HIV To Hit The Markets By 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 The FSH Society , ... the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), ... . The purpose of the campaign is to spread ... most common forms of muscular dystrophies. , To ... the FSH Society will begin sharing impactful photographs of ...
(Date:3/3/2015)... Presale tickets for Madonna will be ready for purchase ... March 9, with Madonna tour tickets expected to sell out ... talented artist is a significant one for fans, and the ... Ticketability.com to browse the inventory of Madonna tickets at ... enjoy, the 2015 tour is expected to attract attention from ...
(Date:3/3/2015)... 2015 State after state prove ... of probation programs aimed to rehabilitate nonviolent drug ... (tax) cost of incarcerating violators of drug laws, ... alcohol addiction treatment. Governor Bruce Rauner ( R)has ... Illinois' drug and alcohol statewide Department of Alcoholism ...
(Date:3/3/2015)... Using an “intelligent,” rather than random, method ... prescription drug coverage plans could save Medicare and patients ... Pittsburgh Graduate School of Public Health analysis discovered. ... of the journal Health Affairs and build upon an ... than $5 billion in its Part D low-income subsidy ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Volpara Solutions, ... announced that John D. Pavlidis has joined their Board ... of technical and executive management experience in the medical ... large and small organizations. , “John’s broad management experience ... imaging modalities will be a tremendous asset to the ...
Breaking Medicine News(10 mins):Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 2Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 3Health News:Presale Tickets for Madonna: Ticketability.com Announces Madonna Tour Tickets for Sale at Reduced Prices for the Rebel Heart Tour During Presales 2Health News:Gov. of Illinois, Bruce Rauner, Suggests Cutting 25 Million for Drug Rehabilitation, Harbor Village Comments 2Health News:Medicare and Patients with Schizophrenia Could Save $150 Million on Part D Plans 2Health News:Medicare and Patients with Schizophrenia Could Save $150 Million on Part D Plans 3Health News:Volpara Solutions Adds Medical Imaging Veteran John Pavlidis to Board of Directors 2Health News:Volpara Solutions Adds Medical Imaging Veteran John Pavlidis to Board of Directors 3
... numbers are staggering --,over 20% of people living in ... the impairment or disability which creates dependency and,poverty in ... and political opportunities," says Ron Nabors, Chief,Executive Officer of ... stand up and speak out on the,International Day for ...
... Oct. 16 Children in the South Bay,suffering ... conditions can,now receive specialty care from Lucile Packard ... hospital,s new South Bay,Specialty Center in Los Gatos ... all the hallmarks of its parent institution. ...
... WEST CHESTER, Ohio, Oct. 16 AtriCure, Inc.,(Nasdaq: ... leader in cardiac surgical,ablation products, today announced that ... which physicians have adopted to,treat atrial fibrillation (AF), ... Dr. James H. McClelland, an,electrophysiologist, and colleagues from ...
... the U.S. Food and Drug,Administration,s (FDA,s) Cardiovascular ... majority of members voted to recommend the ... FOSRENOL(R),(lanthanum carbonate), to treat hyperphosphatemia (elevated levels ... disease (CKD) Stage 4 patients.,Currently, FOSRENOL is ...
... and Advertising ... Distribution Agreements, WebMD Announces Third Quarter Earnings ... WebMD Health Corp. (Nasdaq:,WBMD), the leading provider of health information services, ... Preliminary Results for the Three Months Ended September 30, 2007 ...
... Oct. 16 HLTH Corporation,(Nasdaq: HLTH ) today ... months ended September 30, 2007 at approximately 4:00 pm ... previously announced, HLTH Corporation,s 84% owned,subsidiary, WebMD Health Corp. ... their financial results for the three months ended September ...
Cached Medicine News:Health News:CBM USA stands up and speaks out to world leaders on the International Day for the Eradication of Poverty 2Health News:Packard Children's Hospital Opens New South Bay Specialty Clinic Bringing Specialty Care Close to Home 2Health News:Published Results Using AtriCure Minimally Invasive Products 2Health News:Published Results Using AtriCure Minimally Invasive Products 3Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 2Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 3Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 4Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 5Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 6Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 7Health News:WebMD Reports Preliminary Third Quarter Financial Results 2Health News:WebMD Reports Preliminary Third Quarter Financial Results 3Health News:WebMD Reports Preliminary Third Quarter Financial Results 4Health News:WebMD Reports Preliminary Third Quarter Financial Results 5Health News:WebMD Reports Preliminary Third Quarter Financial Results 6Health News:WebMD Reports Preliminary Third Quarter Financial Results 7Health News:WebMD Reports Preliminary Third Quarter Financial Results 8Health News:WebMD Reports Preliminary Third Quarter Financial Results 9Health News:WebMD Reports Preliminary Third Quarter Financial Results 10Health News:WebMD Reports Preliminary Third Quarter Financial Results 11Health News:HLTH Corporation Announces Third Quarter Earnings Release Date and Conference Call 2
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research and ... addition of Jain PharmaBiotech,s new report "Cardiovascular Drug ... offering. , Drug delivery to the ... because of the anatomy and physiology of the vascular ... of the body. Drugs can be introduced into the ...
(Date:3/3/2015)... 2015  Delcath Systems, Inc. (NASDAQ: ... company focused on oncology with an emphasis on ... announces that the results from its Phase 3 ... been submitted for publication in a leading peer-reviewed ... for Injection for use with the Delcath Hepatic ...
(Date:3/3/2015)... Depomed, Inc. (NASDAQ: DEPO ) today ... Annual Roth Conference in Laguna Niguel ... (9:30 am PT) Tuesday, March 10, 2015. The ... via the Investor Relations page of the Depomed website at ... archived for 30 days on the company,s website. ...
Breaking Medicine Technology:Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 2Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 3Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 2Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 3Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 4Depomed To Present At 27th Annual Roth Conference 2
... control ... with combination therapy -, ... study presents,data demonstrating that patients with Chronic Obstructive Pulmonary ... and symptom control when treated with a,combination of nebulized ...
... Presented at the 2008 International Conference of the American ... ... May 20 Forest Laboratories, Inc. and,Laboratorios Almirall, S.A. today ... of aclidinium bromide, an,investigational treatment for chronic obstructive pulmonary disease ...
Cached Medicine Technology:Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 2Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 3Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 4Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 5
The STAAR ELASTIMIDE™ lens, combines the best of foldable lens technology with traditional design. This lens contains a cast-molded, silicone optic with modified Polyimide haptics....
The STAAR ELASTIC LENS®, is a single piece silicone lens to be placed completely in the capsular bag....
Foldable Silicone Multi-piece Lens....
... Lomb UV-Absorbing, Silicone Posterior Chamber Intraocular Lens ... for the visual correction of aphakia in ... in whom the cataractous lens has been ... device is intended to be placed only ...
Medicine Products: